Mohit Rawat Email & Phone Number

Boston, MA, US

Hamilton, ON, CA

Top business and operational executive for a NASDAQ-listed Radiopharmaceutical Oncology biotech. Key responsibilities include: Business Development and Alliance Management; Development Portfolio & Program Management; Financing, IR and Shareholder/Board management; Commercial Operations

Basel, Switzerland, CH

Basel, Switzerland, CH

Executive Director, CML Lead (TASIGNA®, Asciminib & GLIVEC®)WorldWide Commercial lead for CML franchise - TASIGNA® (~$2B Oncology product), launch lead for Asciminib (ABL001) and GLIVEC®

Basel, Switzerland, CH

• Led US marketing & sales efforts for COSENTYX Brand Strategy, sales force optimization, competitive preparation, customer engagement, market access & patient services etc.
• Led the development of US integrated brand strategy and developed tactical plan with key cross-functional partners to drive ~50% topline growth
• Spearheaded physician segmentation and positioning to customize selling approach to increase ~30% breadth & depth; led physician research, developed strategies & training materials with the field and led roll-out and.
• Led field force expansion efforts to increase Cosentyx breadth, developed the business case, finalized targeting, alignment and field rollout
• Developed launch readiness strategy and cross-functional action-plan for key competitor entering the market to protect key source of business
• Brand lead for Strategic Plan, budget planning, investment trade-offs and business reviews with senior leadership

Basel, Switzerland, CH

• Led pipeline teams, product development strategy, market access & Business Development deals in multiple indications
• Led commercial & financial assessments for licensing deals and mandates for multiple cardio-metabolic diseases
• Defined Novartis strategy for highly competitive NASH market; identified high-value patient segments, optimal trial endpoints, market access levers, and need for diagnostic and capability building for success in a.
• Led pipeline and access team for Ph2/3 asset for NASH/liver indications (#1 portfolio asset for hepatology); defined value proposition, commercial strategy, indication sequencing and financial opportunity for approval.
• Led the pipeline team (marketing, pricing & access, HEOR) for Ph 1/2 asset for multiple CV indications; defined commercial & access strategy, built P&L with regions and achieved successful CEO approval
• Devised comprehensive patient solutions for initiation, monitoring and physician feedback for new pipeline asset

North Chicago, Illinois, US

• Led multiple asset/brand teams to maximize value of new launch and pipeline products in Oncology, Neuroscience and Immunology and interfaced with senior executives and governance bodies
• Responsible for ensuring optimal commercialization and strategic decision making for multiple pre-launch products in Immunology (dermatology, rheumatology, gastro) and Neuroscience franchises
• Led an oral selective JAK-inhibitor product in Immunology, developing strategy and differentiated product profile to address unmet needs, defining optimal positioning in the competitive space and refining pricing &.
• Led a launch MS blockbuster product (ZINBRYTA) in conjunction with partner; developed differentiated positioning, strategic imperatives and target claims, built disease awareness team and initiated launch planning and.
• Helped refine Immunology (Derm, RA) strategy including competitive differentiation and treatment process, key unmet needs, value proposition and positioning of target profiles, prioritization of new products and market.
• Implementation of ‘Asset Playbook’ outlining key commercial and strategic activities to achieve successful broad commercial and regulatory launch (e.g., market opportunity, TPP, value proposition, optimized clinical.

US

• Led healthcare client projects and teams across marketing, business development, strategy, M&A and operationsBusiness development and due diligence
• Managed a team of 5 consultants to prepare a ~$1Bn bid proposal for the CEO of a specialty pharma company
• Led a late stage licensing transaction for a ~$600M specialty product for a mid-sized pharmaco
• Evaluated licensing & acquisition opportunities across oncology, immunology, neuro and other specialty diseases
• Formulated biosimilar strategy and defined clinical & commercial plans for top 10 oncology and immunology targets
• Conducted diligence for top products and potential synergy assessment for a pharma acquisition target

Led the efforts for establishment of a diabetes diagnostic and CV device company

Munich - Germany, DE

• Sourced, evaluated and executed lifescience investments for a $350M global venture capital/growth equity fund
• Deal Execution; Deal Sourcing / Due Diligence; Innovative Investment Model

Zurich, CH

* M&A Advisory and Equity/Debt Financing

Basel, Baselstadt, CH

Led marketing, brand planning and launch execution initiatives supporting high priority launch and pipeline brands

Basel, Baselstadt, CH

Managed the strategic, business & operational activities for a 600-person group for drug, devices and delivery systems

Basel, Baselstadt, CH

• Led the financial planning of development costs and FTEs for the portfolio of development and in-licensed projects
• Successfully managed budget of $200M with team of 10 controllers for resource planning & prioritization decisions

Mba

Ms, Chemical Engineering

B.Tech., Chemical Engineering

Mtech, Process Engineering

Masters In Finance (Fto), Finance & Business